Arvinas delays VERITAC-2 Phase 3 top-line data to Q1 2025

ARVINAS, INC.

Enrollment for vepdegestrant monotherapy trial in 2L breast cancer completed in Q4 2024.
Primary completion date reprojected from November 2024 to January 2025.
Top-line data now expected in the first quarter of 2025 instead of late 2024.
Company and Pfizer cite routine evaluation of blinded event rates for the adjustment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.